CEL-SCI Corporation
(NYSE Amex Equities : CVM)

( )
CVM PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.26%87.921.3%$848.13m
BIIBBiogen Inc.
1.64%220.261.3%$580.78m
AMGNAmgen Inc.
-0.06%186.591.2%$533.06m
ONCESpark Therapeutics, Inc.
0.47%113.5311.2%$497.94m
GILDGilead Sciences, Inc.
0.03%63.790.9%$468.70m
REGNRegeneron Pharmaceuticals, Inc.
0.82%395.002.6%$283.62m
ILMNIllumina, Inc.
-1.65%303.713.5%$275.40m
VRTXVertex Pharmaceuticals Incorporated
1.28%183.851.9%$247.78m
SRPTSarepta Therapeutics, Inc.
-2.73%118.9215.4%$216.64m
BPTHBio-Path Holdings, Inc.
-12.42%19.25190.1%$203.41m
ALXNAlexion Pharmaceuticals, Inc.
1.60%132.292.0%$187.73m
EXASExact Sciences Corporation
0.07%89.0625.3%$173.12m
AAgilent Technologies, Inc.
0.66%79.511.6%$122.76m
IONSIonis Pharmaceuticals, Inc.
0.18%79.048.3%$109.28m
INCYIncyte Corporation
0.80%86.022.5%$93.70m

Company Profile

CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.